| DC Field | Value |
|---|---|
| dc.contributor.author | Youn Jung |
| dc.contributor.author | Yeonhee Ko |
| dc.contributor.author | Ha Young Kim |
| dc.contributor.author | Yong Chan Ha |
| dc.contributor.author | Young‑Kyun Lee |
| dc.contributor.author | Tae‑Young Kim |
| dc.contributor.author | Dong‑soo Choo |
| dc.contributor.author | Sunmee Jang |
| dc.date.accessioned | 2020-02-07T04:47:19Z |
| dc.date.available | 2020-02-07T04:47:19Z |
| dc.date.issued | 2019-01-25 |
| dc.identifier.issn | 0914-8779 |
| dc.identifier.uri | https://repository.kihasa.re.kr/handle/201002/33730 |
| dc.description.abstract | This study examined differences between men and women in factors affecting anti-osteoporosis drug treatment after osteoporotic fracture. Using a national claims database, we analyzed patients aged 50 years and older who experienced their first osteoporotic fracture between January 1, 2008, and December 31, 2012. We examined whether patients were prescribed anti-osteoporosis drugs within 6 months post-fracture. Factors associated with treatment status were identified using multivariate logistic regression. Among a total of 556,410 patients aged 50 and older, only 37% were prescribed anti-osteoporosis drugs within 6 months post-fracture. Female patients with fractures were more likely to receive pharmacotherapy than male patients (41.7 vs. 19.3%). Older age significantly increased the likelihood of receiving anti-osteoporosis drugs after osteoporotic fracture. For men, the adjusted odds ratio for receiving therapy was greatest in those aged 80 years and older (OR 6.4), and for women, it was largest in those aged 70–79 (OR 3.33). Both men and women were more likely to be prescribed drugs after a spine fracture, with men having significantly greater odds of receiving drug therapy (men, OR 7.1, 95% CI 6.5–7.9; women 4.79, CI 4.63–4.96). Patients with rheumatic disease or other osteoporosis-inducing comorbid disease were more likely to be prescribed anti-osteoporosis drugs. Our findings indicate that a lack of anti-osteoporosis pharmacotherapy after fracture remains a problem in Korea, especially among men, highlighting the need for effective quality improvement interventions to maximize post-fracture treatment rates. |
| dc.format.extent | 8 |
| dc.language | eng |
| dc.publisher | Springer/Japanese Society of for Bone and Mineral Research |
| dc.title | Gender differences in anti‑osteoporosis drug treatment after osteoporotic fractures |
| dc.type | Article |
| dc.type.local | Article(Academic) |
| dc.subject.keyword | Fractures |
| dc.subject.keyword | Gender differences |
| dc.subject.keyword | Pharmacotherapy |
| dc.subject.keyword | Post-fracture treatment |
| dc.subject.keyword | Osteoporosis |
| dc.contributor.affiliatedAuthor | Youn Jung |
| dc.identifier.doi | 10.1007/s00774-018-0904-5 |
| dc.identifier.url | https://doi.org/10.1007/s00774-018-0904-5 |
| dc.identifier.localId | KIHASA-3083 |
| dc.citation.title | Journal of Bone and Mineral Metabolism |
| dc.citation.volume | 37 |
| dc.citation.number | 1 |
| dc.citation.date | 2019 |
| dc.citation.startPage | 134 |
| dc.citation.endPage | 141 |
| dc.identifier.bibliographicCitation | Journal of Bone and Mineral Metabolism, vol. 37, no. 1, pp. 134 - 141 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
